LB Pharmaceuticals Inc (LBRX)Healthcare | Biotechnology | New York, United States | NasdaqGM
32.25 USD
-0.70
(-2.124%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 32.25 |
Hot Take ↕ | July 11, 2026, 5:23 a.m. EDT
The investment case for LB Pharmaceuticals is currently bifurcated between a speculative catalyst narrative and deteriorating financial reality. On the surface, the company boasts a pristine balance sheet with negligible debt and massive liquidity, alongside a 'strong buy' analyst consensus driven by potential in its LB-102 pipeline. However, these positives are overshadowed by the stark operational truth: the company is burning cash aggressively, with operating cash flow of -$50 million and negative earnings across the board. This fundamental weakness is reflected in the market's pricing action, which has underperformed significantly over the trailing 200 days despite recent gains. The options market confirms this skepticism, with traders aggressively buying protection at lower strikes for the coming month, suggesting a fear of a sharp correction rather than a continuation of the rally. While the long-term potential exists if the drug succeeds, the current trajectory of cash burn and lack of profitability makes holding the stock a risky proposition until the business model proves it can generate sustainable revenue. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.087599 |
| MSTL_52 | 0.130022 |
| MSTL | 0.145373 |
| AutoARIMA | 0.145456 |
| AutoETS | 0.145502 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.062 |
| Excess Kurtosis | -1.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.916 |
| Market Cap | 924,822,016 |
| Forward P/E | -7.32 |
| Website | https://lbpharma.us |
As of July 11, 2026, 5:23 a.m. EDT: Speculators are positioning for a significant downside move in the near term, evidenced by heavy out-of-the-money put open interest at the $22.5 strike for August expiration, while call activity remains sparse and concentrated at the money. Longer-dated calls show some bullish positioning at $40, but the immediate skew is heavily defensive.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9046242 |
| Address1 | One Pennsylvania Plaza |
| Address2 | Suite 1025 |
| All Time High | 35.345 |
| All Time Low | 13.36 |
| Ask | 32.25 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 411,850 |
| Average Daily Volume3 Month | 258,531 |
| Average Volume | 258,531 |
| Average Volume10Days | 411,850 |
| Bid | 23.19 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 13.206 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 32.25 |
| Current Ratio | 35.675 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 33.82 |
| Day Low | 31.68 |
| Debt To Equity | 0.916 |
| Display Name | LB Pharmaceuticals |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda | -44,755,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.572 |
| Enterprise Value | 562,656,000 |
| Eps Current Year | -3.45167 |
| Eps Forward | -4.40833 |
| Eps Trailing Twelve Months | -1.36 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.3178 |
| Fifty Day Average Change | 1.9321995 |
| Fifty Day Average Change Percent | 0.06373152 |
| Fifty Two Week Change Percent | 90.462425 |
| Fifty Two Week High | 35.345 |
| Fifty Two Week High Change | -3.0950012 |
| Fifty Two Week High Change Percent | -0.08756546 |
| Fifty Two Week Low | 13.36 |
| Fifty Two Week Low Change | 18.89 |
| Fifty Two Week Low Change Percent | 1.4139222 |
| Fifty Two Week Range | 13.36 - 35.345 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,757,597,400,000 |
| Float Shares | 16,260,809 |
| Forward Eps | -4.40833 |
| Forward P E | -7.315696 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0027 |
| Held Percent Institutions | 1.07 |
| Implied Shares Outstanding | 28,676,652 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-09-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York. |
| Long Name | LB Pharmaceuticals Inc |
| Market | us_market |
| Market Cap | 924,822,016 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_413161432 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -38,953,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 944,895,683 |
| Number Of Analyst Opinions | 7 |
| Open | 33.74 |
| Operating Cashflow | -50,370,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 212 605 0300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 32.25 |
| Post Market Time | 1,783,981,120 |
| Previous Close | 32.95 |
| Price Eps Current Year | -9.343304 |
| Price Hint | 2 |
| Price To Book | 2.4420717 |
| Profit Margins | 0.0 |
| Quick Ratio | 33.526 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.700001 |
| Regular Market Change Percent | -2.12443 |
| Regular Market Day High | 33.82 |
| Regular Market Day Low | 31.68 |
| Regular Market Day Range | 31.68 - 33.82 |
| Regular Market Open | 33.74 |
| Regular Market Previous Close | 32.95 |
| Regular Market Price | 32.25 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 134,714 |
| Return On Equity | -0.19555001 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 28,676,652 |
| Shares Percent Shares Out | 0.1587 |
| Shares Short | 4,550,288 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,015,182 |
| Short Name | LB Pharmaceuticals Inc |
| Short Percent Of Float | 0.1909 |
| Short Ratio | 14.19 |
| Source Interval | 15 |
| State | NY |
| Symbol | LBRX |
| Target High Price | 78.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 45.0 |
| Target Median Price | 40.0 |
| Total Cash | 365,636,000 |
| Total Cash Per Share | 12.75 |
| Total Debt | 3,470,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.356825 |
| Two Hundred Day Average Change | 8.893175 |
| Two Hundred Day Average Change Percent | 0.38075274 |
| Type Disp | Equity |
| Volume | 134,714 |
| Website | https://lbpharma.us |
| Zip | 10,119 |